These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1442 related items for PubMed ID: 29808796

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
    Shi X, Chen X, Li X, Lan X, Zhao C, Liu S, Huang H, Liu N, Liao S, Song W, Zhou P, Wang S, Xu L, Wang X, Dou QP, Liu J.
    Clin Cancer Res; 2014 Jan 01; 20(1):151-63. PubMed ID: 24334603
    [Abstract] [Full Text] [Related]

  • 24. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
    Salizzato V, Borgo C, Cesaro L, Pinna LA, Donella-Deana A.
    Oncotarget; 2016 Apr 05; 7(14):18204-18. PubMed ID: 26919095
    [Abstract] [Full Text] [Related]

  • 25. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
    Wu LX, Wu Y, Chen RJ, Liu Y, Huang LS, Lou LG, Zheng ZH, Chen YZ, Xu JH.
    Acta Pharmacol Sin; 2014 Mar 05; 35(3):401-9. PubMed ID: 24487968
    [Abstract] [Full Text] [Related]

  • 26. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.
    Tang C, Schafranek L, Watkins DB, Parker WT, Moore S, Prime JA, White DL, Hughes TP.
    Leuk Lymphoma; 2011 Nov 05; 52(11):2139-47. PubMed ID: 21718141
    [Abstract] [Full Text] [Related]

  • 27. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.
    Kim SJ, Jung KH, Yan HH, Son MK, Fang Z, Ryu YL, Lee H, Lim JH, Suh JK, Kim J, Lee S, Hong S, Hong SS.
    Oncotarget; 2015 Jan 30; 6(3):1507-18. PubMed ID: 25483100
    [Abstract] [Full Text] [Related]

  • 28. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
    Tsubaki M.
    Yakugaku Zasshi; 2018 Jan 30; 138(12):1461-1466. PubMed ID: 30504658
    [Abstract] [Full Text] [Related]

  • 29. JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia.
    Aranda-Tavío H, Recio C, Martín-Acosta P, Guerra-Rodríguez M, Brito-Casillas Y, Blanco R, Junco V, León J, Montero JC, Gandullo-Sánchez L, McNaughton-Smith G, Zapata JM, Pandiella A, Amesty A, Estévez-Braun A, Fernández-Pérez L, Guerra B.
    Biomed Pharmacother; 2021 Dec 30; 144():112330. PubMed ID: 34673425
    [Abstract] [Full Text] [Related]

  • 30. Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.
    Jin B, Wang C, Shen Y, Pan J.
    Cell Death Dis; 2018 Jan 22; 9(2):68. PubMed ID: 29358661
    [Abstract] [Full Text] [Related]

  • 31. Biochemical and chemical characterization of Cynara cardunculus L. extract and its potential use as co-adjuvant therapy of chronic myeloid leukemia.
    Russo A, Perri M, Cione E, Di Gioia ML, Nardi M, Cristina Caroleo M.
    J Ethnopharmacol; 2017 Apr 18; 202():184-191. PubMed ID: 28323047
    [Abstract] [Full Text] [Related]

  • 32. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
    O'Hare T, Eide CA, Deininger MW.
    Expert Opin Investig Drugs; 2008 Jun 18; 17(6):865-78. PubMed ID: 18491988
    [Abstract] [Full Text] [Related]

  • 33. The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia.
    Losson H, Gajulapalli SR, Lernoux M, Lee JY, Mazumder A, Gérard D, Seidel C, Hahn H, Christov C, Dicato M, Kirsch G, Han BW, Schnekenburger M, Diederich M.
    Pharmacol Res; 2020 Oct 18; 160():105058. PubMed ID: 32619722
    [Abstract] [Full Text] [Related]

  • 34. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ.
    Blood; 2004 Oct 15; 104(8):2532-9. PubMed ID: 15256422
    [Abstract] [Full Text] [Related]

  • 35. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM, Jung KH, Kim SJ, Fang Z, Son MK, Yan HH, Lee H, Kim J, Shin S, Hong S, Hong SS.
    Cancer Lett; 2014 Jun 28; 348(1-2):50-60. PubMed ID: 24657654
    [Abstract] [Full Text] [Related]

  • 36. Cryptotanshinone acts synergistically with imatinib to induce apoptosis of human chronic myeloid leukemia cells.
    Ge Y, Yang B, Xu X, Dai Q, Chen Z, Cheng R.
    Leuk Lymphoma; 2015 Mar 28; 56(3):730-8. PubMed ID: 24884318
    [Abstract] [Full Text] [Related]

  • 37. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.
    Lu Z, Jin Y, Chen C, Li J, Cao Q, Pan J.
    Mol Cancer; 2010 May 19; 9():112. PubMed ID: 20482842
    [Abstract] [Full Text] [Related]

  • 38. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
    Lee J, Shen P, Zhang G, Wu X, Zhang X.
    Biomed Pharmacother; 2013 Mar 19; 67(2):157-63. PubMed ID: 23201011
    [Abstract] [Full Text] [Related]

  • 39. Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.
    Borgo C, Cesaro L, Salizzato V, Ruzzene M, Massimino ML, Pinna LA, Donella-Deana A.
    Mol Oncol; 2013 Dec 19; 7(6):1103-15. PubMed ID: 24012109
    [Abstract] [Full Text] [Related]

  • 40. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
    Grimaudo S, Meli M, Di Cristina A, Ferro A, Pipitone MR, Romagnoli R, Simoni D, Dieli F, Tolomeo M.
    Anticancer Drugs; 2013 Apr 19; 24(4):384-93. PubMed ID: 23370613
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 73.